Small cap immunotherapy biotech Immutep is a step closer to commercialising its leading drug candidate, “efti”, after releasing promising data showing the effectiveness of the drug in treating various types of lung, head and neck, and solid tumour cancers.
Immutep CEO Marc Voigt says LAG-3 immunotherapies are now getting noticed by the biotech community.
Loading...
Yolanda Redrup is the editor of the AFR Rich List. She previously reported on technology, healthcare and Street Talk. Connect with Yolanda on Twitter. Email Yolanda at yolanda.redrup@afr.com
